194 related articles for article (PubMed ID: 20559123)
21. Phosphohistone-H3 and Ki-67 immunostaining in cutaneous pilar leiomyoma and leiomyosarcoma (atypical intradermal smooth muscle neoplasm).
Idriss MH; Kazlouskaya V; Malhotra S; Andres C; Elston DM
J Cutan Pathol; 2013 Jun; 40(6):557-63. PubMed ID: 23550775
[TBL] [Abstract][Full Text] [Related]
22. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria.
Ribalta T; McCutcheon IE; Aldape KD; Bruner JM; Fuller GN
Am J Surg Pathol; 2004 Nov; 28(11):1532-6. PubMed ID: 15489659
[TBL] [Abstract][Full Text] [Related]
23. Analysis of tumor mitotic rate in thin metastatic melanomas compared with thin melanomas without metastasis using both the hematoxylin and eosin and anti-phosphohistone 3 IHC stain.
Thareja S; Zager JS; Sadhwani D; Thareja S; Chen R; Marzban S; Jukic DM; Glass LF; Messina J
Am J Dermatopathol; 2014 Jan; 36(1):64-7. PubMed ID: 24451214
[TBL] [Abstract][Full Text] [Related]
24. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
25. Phosphohistone H3 expression correlates with manual mitotic counts and aids in identification of "hot spots" in fibroepithelial tumors of the breast.
Ginter PS; Shin SJ; Liu Y; Chen Z; D'Alfonso TM
Hum Pathol; 2016 Mar; 49():90-8. PubMed ID: 26826415
[TBL] [Abstract][Full Text] [Related]
26. Mitotic rate in cutaneous melanomas ≤1 mm in thickness: a prospective study.
Litzner BR; Etufugh CN; Stepenaskie S; Hynan LS; Cockerell CJ
Am J Dermatopathol; 2012 Dec; 34(8):827-32. PubMed ID: 22878366
[TBL] [Abstract][Full Text] [Related]
27. Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study.
Veras E; Malpica A; Deavers MT; Silva EG
Int J Gynecol Pathol; 2009 Jul; 28(4):316-21. PubMed ID: 19483635
[TBL] [Abstract][Full Text] [Related]
28. A probabilistic analysis of mitotic counts in melanoma.
Vollmer RT
Am J Clin Pathol; 2014 Feb; 141(2):213-8. PubMed ID: 24436268
[TBL] [Abstract][Full Text] [Related]
29. Serine 2481-autophosphorylation of mammalian target of rapamycin (mTOR) couples with chromosome condensation and segregation during mitosis: confocal microscopy characterization and immunohistochemical validation of PP-mTOR(Ser2481) as a novel high-contrast mitosis marker in breast cancer core biopsies.
Lopez-Bonet E; Vazquez-Martin A; Pérez-Martínez MC; Oliveras-Ferraros C; Pérez-Bueno F; Bernadó L; Menendez JA
Int J Oncol; 2010 Jan; 36(1):107-15. PubMed ID: 19956839
[TBL] [Abstract][Full Text] [Related]
30. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging.
Gimotty PA; Guerry D; Ming ME; Elenitsas R; Xu X; Czerniecki B; Spitz F; Schuchter L; Elder D
J Clin Oncol; 2004 Sep; 22(18):3668-76. PubMed ID: 15302909
[TBL] [Abstract][Full Text] [Related]
31. Mitotic rate in primary melanoma: interobserver and intraobserver reliability, analyzed using H&E sections and immunohistochemistry.
Garbe C; Eigentler TK; Bauer J; Blödorn-Schlicht N; Cerroni L; Fend F; Hantschke M; Kurschat P; Kutzner H; Metze D; Mielke V; Preßler H; Reusch M; Reusch U; Stadler R; Tronnier M; Yazdi A; Metzler G
J Dtsch Dermatol Ges; 2016 Sep; 14(9):910-5. PubMed ID: 27607033
[TBL] [Abstract][Full Text] [Related]
32. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
[TBL] [Abstract][Full Text] [Related]
33. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
[TBL] [Abstract][Full Text] [Related]
34. Validation of mitosis counting by automated phosphohistone H3 (PHH3) digital image analysis in a breast carcinoma tissue microarray.
Dessauvagie BF; Thomas C; Robinson C; Frost FA; Harvey J; Sterrett GF
Pathology; 2015 Jun; 47(4):329-34. PubMed ID: 25938351
[TBL] [Abstract][Full Text] [Related]
35. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
[TBL] [Abstract][Full Text] [Related]
36. Scoring the percentage of Ki67 positive nuclei is superior to mitotic count and the mitosis marker phosphohistone H3 (PHH3) in terms of differentiating flat lesions of the bladder mucosa.
Gunia S; Kakies C; Erbersdobler A; Koch S; May M
J Clin Pathol; 2012 Aug; 65(8):715-20. PubMed ID: 22554964
[TBL] [Abstract][Full Text] [Related]
37. Phosphohistone H3: new standard IHC marker for grading tumors via mitotic indexing.
Yang GG
MLO Med Lab Obs; 2011 Jul; 43(7):20, 23. PubMed ID: 21830653
[No Abstract] [Full Text] [Related]
38. Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Schmidt H; Steiniche T
Diagn Pathol; 2016 Apr; 11():35. PubMed ID: 27062658
[TBL] [Abstract][Full Text] [Related]
39. Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody.
Medani H; Elshiekh M; Naresh KN
J Clin Pathol; 2021 Oct; 74(10):646-649. PubMed ID: 32873701
[TBL] [Abstract][Full Text] [Related]
40. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma.
Vaquerano J; Kraybill WG; Driscoll DL; Cheney R; Kane JM
Ann Surg Oncol; 2006 Feb; 13(2):198-204. PubMed ID: 16418885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]